Reuters logo
BRIEF-Argen X launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients
December 15, 2016 / 6:13 AM / a year ago

BRIEF-Argen X launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients

Dec 15 (Reuters) - Argen X Bv :

* Argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients

* Top-line data from the dose escalation are expected in about 18 months Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below